However, ACT with lower doses of SRC-3 KO Tregs (2: 326K cells and 4: 230K cells) suppressed breast tumor growth compared to ACT with purified wild-type Tregs but did not eradicate breast tumors (Fig. 5B and SI Appendix, Fig. S13C). The gene discussed is NCOA3; the disease is breast neoplasm.